Record Details

Novel amylomacins from seaweed‐associated Bacillus amyloliquefaciens as prospective antimicrobial leads attenuating resistant bacteria

CMFRI Repository

View Archive Info
 
 
Field Value
 
Relation http://eprints.cmfri.org.in/15426/
https://link.springer.com/article/10.1007%2Fs11274-021-03161-9
10.1007/s11274-021-03161-9
 
Title Novel amylomacins from seaweed‐associated Bacillus
amyloliquefaciens as prospective antimicrobial leads attenuating resistant bacteria
 
Creator Chakraborty, Kajal
Vinaya, K K
Joy, Minju
Chakraborty, Rekha D
 
Subject Bioactive compounds
Biochemical composition
Biochemistry
Seaweed
 
Description The rise in antibiotic-resistant bacterial strains prompting nosocomial infections drives the search for new bioactive sub-
stances of promising antibacterial properties. The surfaces of seaweeds are rich in heterotrophic bacteria with prospective

antimicrobial substances. This study aimed to isolate antibacterial leads from a seaweed-associated bacterium. Heterotrophic

Bacillus amyloliquefaciens MTCC 12716 associated with the seaweed Hypnea valentiae, was isolated and screened for anti-
microbial properties against drug-resistant pathogens. The bacterial crude extract was purifed and three novel amicoumacin-
class of isocoumarin analogues, 11′-butyl acetate amicoumacin C (amylomacin A), 4′-hydroxy-11′-methoxyethyl carboxylate

amicoumacin C (amylomacin B) and 11′-butyl amicoumacin C (amylomacin C) were isolated to homogeneity. The studied
amylomacins possessed potential activities against Pseudomonas aeruginosa, vancomycin-resistant Enterococcus faecalis,
Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, and Shigella fexneri with a range of minimum inhibitory
concentration values from 0.78 to 3.12 μg/mL, although standard antibiotics ampicillin and chloramphenicol were active at

6.25–25 μg/mL. Noticeably, the amylomacin compound encompassing 4′-hydroxy-11′-methoxyethyl carboxylate amicou-
macin C functionality (amylomacin B), displayed considerably greater antagonistic activities against methicillin-resistant S.

aureus, vancomycin-resistant E. faecalis, Vibrio parahaemolyticus, Escherichia coli, and K. pneumoniae (minimum inhibitory
concentration 0.78 μg/mL) compared to the positive controls and other amylomacin analogues. Antimicrobial properties of
the amylomacins, coupled with the presence of polyketide synthase-I/non-ribosomal peptide synthetase hybrid gene attributed
the bacterium as a promising source of antimicrobial compounds with pharmaceutical and biotechnological applications.
 
Publisher Springer
 
Date 2021
 
Type Article
PeerReviewed
 
Format text
 
Language en
 
Identifier http://eprints.cmfri.org.in/15426/1/World%20Journal%20of%20Microbiology%20and%20Biotechnology_2021_Kajal%20Chakraborty.pdf
Chakraborty, Kajal and Vinaya, K K and Joy, Minju and Chakraborty, Rekha D (2021) Novel amylomacins from seaweed‐associated Bacillus amyloliquefaciens as prospective antimicrobial leads attenuating resistant bacteria. World Journal of Microbiology and Biotechnology. pp. 1-12.